BioAdaptives Inc
BioAdaptives, Inc. investigates, markets, and distributes natural plant, algal, and mushroom-based products and medical devices for humans and animals. It offers nutraceutical products, such as dietary supplements. The company offers Human Clinical trial; Zeranovia, a natural ingredient and uses proprietary methods of optimizing the availability of nutrients in foods and beverages; Lung Flute, a … Read more
BioAdaptives Inc (BDPT) - Net Assets
Latest net assets as of September 2025: $-1.47 Million USD
Based on the latest financial reports, BioAdaptives Inc (BDPT) has net assets worth $-1.47 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($124.36K) and total liabilities ($1.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.47 Million |
| % of Total Assets | -1178.2% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 9896.38 |
BioAdaptives Inc - Net Assets Trend (2013–2024)
This chart illustrates how BioAdaptives Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioAdaptives Inc (2013–2024)
The table below shows the annual net assets of BioAdaptives Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-1.46 Million | +11.10% |
| 2023-12-31 | $-1.65 Million | -13.44% |
| 2022-12-31 | $-1.45 Million | -32.79% |
| 2021-12-31 | $-1.09 Million | +20.72% |
| 2020-12-31 | $-1.38 Million | -64.17% |
| 2019-12-31 | $-839.88K | -21.06% |
| 2018-12-31 | $-693.74K | -19892.90% |
| 2017-12-31 | $3.50K | +101.99% |
| 2016-12-31 | $-176.36K | +13.28% |
| 2015-12-31 | $-203.37K | -173723.93% |
| 2014-12-31 | $-117.00 | -100.13% |
| 2013-12-31 | $88.47K | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioAdaptives Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 914502700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $821.00 | % |
| Other Components | $7.70 Million | % |
| Total Equity | $-1.46 Million | 100.00% |
BioAdaptives Inc Competitors by Market Cap
The table below lists competitors of BioAdaptives Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Focus Home Interactive Société anonyme
STU:0HF
|
$147.49K |
|
Sparindex INDEX Europa Forsvar
CO:SPIIEF
|
$147.51K |
|
NHK SPRING (NHK.SG)
STU:NHK
|
$147.52K |
|
Technoplus Ventures Ltd
TA:TNPV
|
$147.57K |
|
Amphastar Pharmaceuticals Inc
STU:29A
|
$147.20K |
|
ROLLS-ROYCE HLDGS
MU:RRU
|
$147.17K |
|
Wealth Invest AKL AlphaCura 0/50/100 W
CO:WEIACW
|
$147.07K |
|
R STAHL N
BE:RSL2
|
$147.02K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioAdaptives Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,646,631 to -1,463,918, a change of 182,713.
- Net loss of 899,000 reduced equity.
- New share issuances of 294,115 increased equity.
- Other comprehensive income increased equity by 285.
- Other factors increased equity by 787,313.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-899.00K | -61.41% |
| Share Issuances | $294.12K | +20.09% |
| Other Comprehensive Income | $285.00 | +0.02% |
| Other Changes | $787.31K | +53.78% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares BioAdaptives Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.01 | $0.10 | x |
| 2014-12-31 | $0.00 | $0.10 | x |
| 2015-12-31 | $-2.40 | $0.10 | x |
| 2016-12-31 | $-1.89 | $0.10 | x |
| 2017-12-31 | $0.04 | $0.10 | x |
| 2018-12-31 | $-6.13 | $0.10 | x |
| 2019-12-31 | $-6.75 | $0.10 | x |
| 2020-12-31 | $-10.14 | $0.10 | x |
| 2021-12-31 | $-4.86 | $0.10 | x |
| 2022-12-31 | $-2.05 | $0.10 | x |
| 2023-12-31 | $-0.28 | $0.10 | x |
| 2024-12-31 | $-0.18 | $0.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioAdaptives Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7096.06%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-150.32%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -20.66% | 0.00% | 0.00x | 1.36x | $-27.13K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.57 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-207.09K |
| 2016 | 0.00% | -899.75% | 0.13x | 0.00x | $-153.71K |
| 2017 | -1783.14% | 0.00% | 0.00x | 1.02x | $-62.85K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.34 Million |
| 2019 | 0.00% | -4411.58% | 0.41x | 0.00x | $-354.26K |
| 2020 | 0.00% | -6599.94% | 0.87x | 0.00x | $-939.69K |
| 2021 | 0.00% | -5309.47% | 0.13x | 0.00x | $-940.70K |
| 2022 | 0.00% | -5216.58% | 0.46x | 0.00x | $-750.85K |
| 2023 | 0.00% | -2492.56% | 0.27x | 0.00x | $-547.34K |
| 2024 | 0.00% | -7096.06% | 0.05x | 0.00x | $-752.61K |
Industry Comparison
This section compares BioAdaptives Inc's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $5,681,533,529
- Average return on equity (ROE) among peers: 0.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioAdaptives Inc (BDPT) | $-1.47 Million | -20.66% | N/A | $147.23K |
| Above Food Ingredients Inc. Common Stock (ABVE) | $30.90K | -3.31% | 7.66x | $18.76 Million |
| The a2 Milk Company Limited (ACOPF) | $7.27 Million | -30.19% | 0.14x | $3.91 Billion |
| Ayujoy Herbals Ltd (AJOY) | $22.20 Million | 29.29% | 0.00x | $95.71 |
| Alfa S.A.B. de C.V (ALFFF) | $53.35 Billion | 7.36% | 3.80x | $2.16 Billion |
| Amincor Inc (AMNCB) | $34.44 Million | -63.76% | 0.81x | $2.24K |
| Armanino Foods New (AMNF) | $21.40 Million | 30.30% | 0.33x | $72.33K |
| Amira Nature Foods Ltd (ANFIF) | $303.22 Million | 8.27% | 0.89x | $128.79 |
| AAK AB (publ.) (ARHUF) | $2.44 Billion | 12.85% | 2.63x | $5.07 Billion |
| Artisan Consumer Goods Inc (ARRT) | $-326.75K | 0.00% | 0.00x | $279.39K |
| ARYZTA AG (ARZTF) | $632.10 Million | 9.58% | 2.04x | $53.13 Million |